1 min read
Add as a preferred source on Google

Regeneron and Alnylam Win FDA Approval for Livsayis in Adults

The RNA therapeutic, identified as Livsayis (cemdisiran), was approved to treat adults with myasthenia gravis, a chronic autoimmune condition.

A medicine vial and syringe rest on a clean clinical counter / TokenPost.ai
A medicine vial and syringe rest on a clean clinical counter / TokenPost.ai

The Food and Drug Administration approved Livsayis (cemdisiran), a small interfering RNA therapeutic developed by Regeneron Pharmaceuticals with Alnylam Pharmaceuticals, for adults with myasthenia gravis, a chronic autoimmune condition.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…